Prostate Cancer
Pipeline by Development Stage
Drug Modality Breakdown
Prostate Cancer is a ~$2.2B Part D market with mature, androgen-receptor-focused therapeutics entering consolidation as patent cliffs approach.
Key Trends
- Androgen receptor (AR) inhibitors dominate 73% of market share (ERLEADA + NUBEQA); GnRH agonists/antagonists represent legacy backbone therapy
- Patent cliff risk: RAYOS (2028), LUPRON DEPOT (approaching), and peak-lifecycle AR inhibitors face LOE by 2040–2042
- Minimal pipeline innovation: 1,759 trials ongoing but heavily weighted to Phase 2 (537 trials); few emerging mechanisms beyond established AR/GnRH pathways
Career Verdict
A stable, commercially mature area suitable for specialists seeking market depth and legacy-drug stewardship, but limited upside for those pursuing cutting-edge oncology innovation.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ERLEADA (apalutamide) | Johnson & Johnson | $1.1B | 50% | Peak | Stable | 13.7yr |
| 2 | NUBEQA (darolutamide) | Bayer | $576M | 26% | Peak | Stable | 16.1yr |
| 3 | ORGOVYX (relugolix) | Sumitomo Dainippon Pharma | $277M | 13% | Peak | Stable | 11.4yr |
| 4 | LUPRON DEPOT (leuprolide acetate) | AbbVie | $129M | 6% | LOE_Approaching | Declining |
Drug Class Breakdown
market consolidation around ERLEADA + NUBEQA duopoly
legacy backbone; gradual erosion as AR inhibitors preferred
minimal market penetration; largely displaced by newer AR inhibitors
niche; limited clinical relevance in primary market
Career Outlook
StableProstate cancer represents a mature, consolidating market with predictable commercial dynamics and strong incumbency by J&J and Bayer. Job security is high, compensation competitive, and career paths well-defined; however, innovation velocity is low and disruption risk is concentrated in patent cliff windows (2028–2042). Specialists should expect steady-state market management over the next 5–7 years, followed by portfolio restructuring and potential layoffs as cliffs approach.
Breaking In
Entry-level professionals should prioritize Medical Affairs or Commercial roles at J&J, Bayer, or AstraZeneca to build oncology credibility in a stable, well-funded portfolio before seeking higher-risk innovation roles elsewhere.
For Experienced Professionals
Experienced oncology professionals should consider this market for board-level or VP-level roles within established companies, or pivot to emerging mechanisms (ADCs, immunotherapy combos) at biotech to future-proof careers against 2040+ patent cliffs.
In-Demand Skills
Best For
Hiring Landscape
8,207 total jobs across the prostate cancer specialist ecosystem, with Commercial (1,915 roles) and Engineering (547 roles) driving majority of openings. Johnson & Johnson, AstraZeneca, and AbbVie lead hiring with 1,798, 1,373, and 1,495 jobs respectively, reflecting their dominance in the market. Medical Affairs ($302K avg) and Commercial ($225K avg) offer the highest-value career tracks.
By Department
Stable hiring across established players, but growth limited; opportunities concentrate in Commercial and Medical Affairs for those seeking high-impact roles in a mature, well-resourced market.
On Market (10)
Approved therapies currently available
Competitive Landscape
179 companies ranked by most advanced pipeline stage
+149 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 48 trials with date data
Clinical Trials (50)
Total enrollment: 7,975 patients across 50 trials
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy
Phase IV Study to Evaluate Bone Mineral Density in No-bone Metastatic Prostate Cancer Treated With Degarelix
A Study of ELIGARD® in Hormone-dependent Prostate Cancer Patients
Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer
A Trial to Evaluate Safety of Firmagon® (Degarelix) in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer
A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment
A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer
A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide
A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients.
GP Extended Action Triptorelin
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse
Efficacy and Safety of Single Dose of 5 mg Zoledronic Acid in Chinese Patients With Paget's Disease of Bone (PDB)
Re-treatment of Participants With Paget's Disease Using Zoledronic Acid
Feasibility of Doctors' Rooms-based Infusion of Zoledronic Acid
µMRI of Therapeutic Intervention in Postmenopausal Osteoporosis
Impact on Reducing the Incidence of Low Serum Calcium by Providing Educational Materials on the Need to Take Daily Supplemental Calcium and Vitamin D to Patients With Paget's Disease Treated With Reclast®
Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases
Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
Assessment of Pain and Quality of Life in Breast and Prostate Cancer Patients With Bone Metastases
Non-small Cell Lung Cancer Registry
A Multiple Myeloma Trial in Patients With Bone Metastases
Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis
CMAB vs IMAB in Metastatic Prostate Cancer
Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma.
Evaluation of Efficacy of Zoledronic Acid in Patients With Haemoglobin Syndromes (Thalassemia and Sicle Cell Anaemia) and Risk of Skeletal Events
A Study to Evaluate the Efficacy and Tolerability of Zoledronic Acid in Patients With Metastatic Prostate Cancer Who Can be Treated With a Group of Medications Known as Bisphosphonates
Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis
Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
Study Comparing Full-dose Radiotherapy Versus Reduced Dose in the Management of Bone Metastasis in Patients With Breast Cancer Receiving Zoledronic Acid
Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis
Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
Comparison of Pamidronate With Zoledronic Acid for Transplant Related Bone Loss Prevention
Efficacy and Tolerability of Zoledronic Acid With Radiotherapy in Pts With Advanced Osteolytic Bone Lesions
Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
The Effect of Zoledronic Acid on Bone Density in Liver Transplant Patients
Study of a Drug [DCVax (tm)-Prostate] to Treat Prostate Cancer When Hormone Therapy is no Longer Effective.
Comparing Two Different Boost Approaches in Radiation Therapy for People With Prostate Cancer
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Efficacy, Safety, and Pharmacokinetics of FP-014, 11.25 mg in Patients With Advanced Prostate Cancer
Efficacy, Safety, and Pharmacokinetics of FP-014, 22.5 mg in Patients With Advanced Prostate Cancer
Related Jobs in Oncology
Senior Manager, Supply Chain
Senior Associate Scientist, Biology
Director, Intellectual Property
Bioinformatics Research Scientist II
Senior Oncology Account Specialist Prostate Cancer Las Vegas, NV
Desktop Support Specialist
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.